Oncologists' agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2-early breast cancer

被引：0
|
作者：
Castro-Henriques, M. [1 ]
Casadevall Aguilar, D. [2 ]
Monzonis, X. [2 ]
Martinez-Garcia, M. [2 ]
Martos, T. [2 ]
Corbera, A. [2 ]
Trias Bes, I. Tusquets [2 ]
Albanell, J. [2 ]
Servitja, S. [2 ]
机构：
[1] HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Barcelona, Spain
[2] Hosp del Mar, Med Oncol Dept, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
186P
引用
收藏
页码：S317 / S317
页数：1
相关论文
共 50 条
  • [1] Does the 21-gene recurrence score have clinical utility in HR+/HER2+breast cancer?
    Bilani, Nadeem
    Crowley, Fionnuala
    Mohanna, Mohamed
    Itani, Mira
    Yaghi, Marita
    Saravia, Diana
    Jabbal, Iktej
    Dominguez, Barbara
    Liang, Hong
    Nahleh, Zeina
    BREAST, 2022, 66 : 49 - 53
  • [2] Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2-Early Breast Cancer
    Jacobs, Flavia
    Gaudio, Mariangela
    Benvenuti, Chiara
    De Sanctis, Rita
    Santoro, Armando
    Zambelli, Alberto
    CANCERS, 2023, 15 (01)
  • [3] Outcomes in Premenopausal Patients with HR+/HER2-Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score
    Bilani, Nadeem
    Patel, Rima
    Crowley, Fionnuala
    Tiersten, Amy
    ONCOLOGIST, 2023, : 1049 - 1054
  • [4] Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HP2-Early Breast Cancer
    Nitz, Ulrike A.
    Gluz, Oleg
    Kuemmel, Sherko
    Christgen, Matthias
    Braun, Michael
    Aktas, Bahriye
    Luedtke-Heckenkamp, Kerstin
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Schumacher, Claudia
    Darsow, Maren
    Krauss, Katja
    Nuding, Benno
    Thill, Marc
    Potenberg, Jochem
    Uleer, Christoph
    Warm, Mathias
    Fischer, Hans Holger
    Malter, Wolfram
    Hauptmann, Michael
    Kates, Ronald E.
    Graeser, Monika
    Wuerstlein, Rachel
    Shak, Steven
    Baehner, Frederick
    Kreipe, Hans H.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2557 - +
  • [5] First prospective multicenter Italian study on the impact of the 21-gene recurrence score® (RS) in adjuvant clinical decisions for ER +/HER2-early breast cancer patients
    Dieci, M. V.
    Guarneri, V.
    Mion, M.
    Tortora, G.
    Morandi, P.
    Gori, S.
    Merlini, L.
    Oliani, C.
    Pasini, F.
    Bonciarelli, G.
    Orvieto, E.
    Del Bianco, P.
    De Salvo, G. L.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast Cancer
    Kwon, Mi Jeong
    Ryu, Jai Min
    Cho, Soo Youn
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeeyeon
    Lee, Soo Jung
    Park, Ji-Young
    Park, Ho Yong
    Hong, Sungjun
    Kim, Kyunga
    Han, Jinil
    Moon, Youngho
    Shin, Young Kee
    Lee, Jeong Eon
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Predictive value of multigene assay for chemotherapy benefit in patients with HR+/HER2-early breast cancer
    Kwon, Mi Jeong
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C. -S.
    Wei, R.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    SWISS MEDICAL WEEKLY, 2022, 152 : 48S - 48S
  • [9] Patient Preferences for HR+/HER2-Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment
    Harmer, Victoria
    Ammendolea, Cathy
    Ryan, Mandy
    Boyle, Frances
    Werutsky, Gustavo
    El Mouzain, Dina
    Marshall, Deborah A.
    Thomas, Caitlin
    Heidenreich, Sebastian
    Lu, Hui
    Krucien, Nicolas
    Payan, Juan Mora
    Aubel, Dawn
    Danyliv, Andriy
    Pathak, Purnima
    Harbeck, Nadia
    BREAST CARE, 2025, 20 (01)
  • [10] Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2-Early Breast Cancer in China
    Li, Q.
    Jiang, M.
    Liu, J.
    Zhang, M.
    Xu, B.
    BREAST, 2025, 80
12345